Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MedTech-related health technology assessments from NIHR in September 2021

The National Institute for Health Research (NIHR) funds valuable independent research for health and social care decision-makers in England. Reports from the Health Technology Assessment (HTA) Programme are published in the NIHR HTA Journal and inform NICE guidance.

In September 2021, two MedTech-related assessments were published in the NIHR HTA Journal:

  • Non-invasive imaging software to assess the functional significance of coronary stenoses: a systematic review and economic evaluation. Two products were assessed: QAngio XA 3D/QFR (three-dimensional/quantitative flow ratio) and CAAS vFFR (vessel fractional flow reserve). It was concluded that the quantitative flow ratio measured by QAngio XA 3D/QFR has a good agreement and diagnostic accuracy compared with invasive FFR and is preferable to standard invasive coronary angiography alone. QAngio XA 3D/QFR has similar cost-effectiveness to invasive FFR and, therefore, could be a reasonable alternative. The clinical effectiveness and cost-effectiveness of CAAS vFFR are uncertain.
  • A prognostic model, including quantitative fetal fibronectin, to predict preterm labor: the QUIDS meta-analysis and prospective cohort study Measurement of fetal fibronectin in vaginal fluid is a biochemical test that can indicate impending preterm birth. It was concluded that a prognostic model including quantitative fetal fibronectin and clinical risk factors showed excellent performance in the prediction of spontaneous preterm birth within seven days of the test. The model is cost-effective and can be used to help guide management decisions for women with threatened preterm labor. The model will be embedded in electronic maternity records and a mobile application, enabling further data collection for refinement and validation.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).